Metoprolol Retard Teva (Metoprolol Succinate)

Metoprolol succinate is indicated for several cardiovascular conditions where beta‑1 adrenergic blockade improves outcomes.

• Hypertension: reduces systolic and diastolic blood pressure by decreasing heart rate and cardiac output.
• Chronic stable angina: lessens myocardial oxygen demand, relieving chest pain during exertion.
• Heart failure (reduced ejection fraction): improves survival and reduces hospitalisations by lowering ventricular workload.
• Post‑myocardial infarction: decreases the risk of recurrent infarction and arrhythmias by stabilising heart rhythm.

• Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, diminishing sympathetic stimulation. This leads to a slower heart rate, reduced myocardial contractility, and lower stroke volume, collectively decreasing cardiac output and arterial pressure. The extended‑release formulation provides a steady plasma concentration, allowing once‑daily dosing and consistent haemodynamic control.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Fatigue: feeling unusually tired or weak.
• Dizziness: light‑headedness, especially when standing quickly.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects

• Heart block: impaired electrical conduction requiring medical attention.
• Severe bronchospasm: difficulty breathing, particularly in patients with asthma.
• Hypotension: markedly low blood pressure causing fainting.
• Depression or mood changes: new or worsening depressive symptoms.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Cardiac function: assess baseline heart rate and blood pressure.
• Respiratory disease: use cautiously in patients with asthma or chronic obstructive pulmonary disease.
• Diabetes: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms.
• Concomitant drugs: review other medications that affect heart rate or blood pressure.
• Pregnancy and lactation: evaluate risk‑benefit ratio; data are limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metoprolol succinate can interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid)

• Non‑selective beta‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block.
• CYP2D6 inhibitors (e.g., quinidine, paroxetine): increased metoprolol plasma levels.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: may mask hypoglycaemia signs.
• NSAIDs: can reduce antihypertensive effect.
• Diuretics: may potentiate orthostatic hypotension.
• Antidepressants (tricyclics): enhanced bradycardic effect.